News
TELA
2.770
-2.46%
-0.070
TELA BIO ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12h ago
Weekly Report: what happened at TELA last week (1202-1206)?
Weekly Report · 4d ago
Weekly Report: what happened at TELA last week (1125-1129)?
Weekly Report · 12/02 12:25
Weekly Report: what happened at TELA last week (1118-1122)?
Weekly Report · 11/25 12:13
Analysts Are Bullish on These Healthcare Stocks: Keros Therapeutics (KROS), Ceribell, Inc. (CBLL)
TipRanks · 11/22 12:01
TELA Bio Set for Growth with Strategic Enhancements and Financial Improvements
TipRanks · 11/22 12:00
Weekly Report: what happened at TELA last week (1111-1115)?
Weekly Report · 11/18 12:09
TELA Bio’s Strong Financial Performance and Strategic Positioning Justify Buy Rating
TipRanks · 11/13 06:05
Weekly Report: what happened at TELA last week (1104-1108)?
Weekly Report · 11/11 12:29
TELA Bio, Inc. Reports Financial Results for the Quarter Ended September 30, 2024
Press release · 11/09 00:12
Tela Bio price target lowered to $5 from $8 at Piper Sandler
TipRanks · 11/08 15:06
Deep Dive Into TELA Bio Stock: Analyst Perspectives (6 Ratings)
Benzinga · 11/08 15:01
TELA Bio Price Target Cut to $5.00/Share From $8.00 by Piper Sandler
Dow Jones · 11/08 13:57
TELA Bio Is Maintained at Overweight by Piper Sandler
Dow Jones · 11/08 13:57
Piper Sandler Maintains Overweight on TELA Bio, Lowers Price Target to $5
Benzinga · 11/08 13:47
TELA Bio’s Strategic Recovery and Growth Potential: A Buy Rating with a $12 Target
TipRanks · 11/08 13:45
TELA Bio GAAP EPS of -$0.42 beats by $0.03, revenue of $18.96M beats by $0.11M
Seeking Alpha · 11/08 10:11
TELA Bio, Inc. Reports Record Revenue Growth
TipRanks · 11/08 05:24
TELA Bio, Inc. (TELA) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 11/07 23:20
Tela Bio backs FY24 revenue view $74.5M-$76.5M, consensus $74.4M
TipRanks · 11/07 22:07
More
Webull provides a variety of real-time TELA stock news. You can receive the latest news about Tela Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TELA
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.